| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | April 29, 2022 |
| Accession Number: | 0001193125-22-117697 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/31/2022 | $11.00 → $3.00 | Buy | Chardan Capital |
| 11/12/2021 | $15.00 → $11.00 | Buy | Chardan Capital |
| 11/3/2021 | $25.00 → $22.00 | Market Outperform | JMP Securities |
| 10/19/2021 | $3.00 | Equal-Weight → Underweight | Morgan Stanley |
15-12B - Kaleido Biosciences, Inc. (0001751299) (Filer)
EFFECT - Kaleido Biosciences, Inc. (0001751299) (Filer)
S-8 POS - Kaleido Biosciences, Inc. (0001751299) (Filer)
KB295 reached its primary endpoint demonstrating favorable safety and tolerability profile Reduction in key ulcerative colitis biomarkers correlated with disease activity and inflammation - fecal calprotectin, fecal lactoferrin, and FimH - observed at end of study Virtual R&D Presentation, highlighting the ulcerative colitis and chronic obstructive pulmonary disease programs, to be held today at 8:00 a.m. ET LEXINGTON, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore g
Latest data and clinical development plans for KB295 in ulcerative colitis (UC) to be presented Call to feature leading experts in UC and Chronic Obstructive Pulmonary Disease (COPD) Company plans to advance both KB295 and KB109 to Phase 2 studies LEXINGTON, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that it will host a virtual R&D Presentation on October 5, 2021, at 8 a.m. ET. The agenda will feature an update on the Company's corporate strategy, data from the non-IND stu
4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)
4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)
4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)
SC 13G/A - Kaleido Biosciences, Inc. (0001751299) (Subject)
SC 13G/A - Kaleido Biosciences, Inc. (0001751299) (Subject)
SC 13G - Kaleido Biosciences, Inc. (0001751299) (Subject)
Chardan Capital reiterated coverage of Kaleido Biosciences with a rating of Buy and set a new price target of $3.00 from $11.00 previously
Chardan Capital reiterated coverage of Kaleido Biosciences with a rating of Buy and set a new price target of $11.00 from $15.00 previously
JMP Securities reiterated coverage of Kaleido Biosciences with a rating of Market Outperform and set a new price target of $22.00 from $25.00 previously
CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs. Prior to ORDR, she worked at the U.S. Food and Drug Administration (FDA) Center for
CAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors. Grant brings nearly 40 years of agricultural and corporate leadership, including as Chairman, President, and Chief Executive Officer of the former Monsanto Company, a global provider of technology-based solutions and agricultural products. During h
CAMBRIDGE, Mass., Jan. 26, 2022 /PRNewswire/ -- Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent and tunable medicines, has appointed Stuart Milstein, Ph.D., to the newly created position of Senior Vice President and Head of Platform Biology. Dr. Milstein most recently served as the Vice President of platform biology at Korro Bio, Inc., and previously led the RNAi Lead Development group at Alnylam Pharmaceuticals, Inc. Dr. Milstein will be responsible for advancing Senda's platform and scaling the Company's efforts to unlock a new class of fully programmable medicines.
Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting season. Lyra Therapeutics, Inc. (NASDAQ:LYRA) was among the biggest gainers of the week following the completion of a $100.5 million private placement. Sierra Oncology, Inc. (NASDAQ:SRRA) also advanced strongly after it announced a deal to be acquired by GlaxoSmithKline plc (NYSE:GSK) for $1.9 billion. Meanwhile, Kaleido Biosciences, Inc. (NASDAQ:KLDO) plunged after disclosing in a filing that it is shuttering operations. The microbiome therapeutic-focused biopharma was facing a cash crunch
Gainers Kaleido Biosciences (NASDAQ:KLDO) stock increased by 10.3% to $0.32 during Thursday's after-market session. Today's trading volume for this security ended up closing at 14.2 million shares, which is 369.4 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $13.6 million. NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares moved upwards by 9.28% to $0.95. At the close, NeuroBo Pharmaceuticals's trading volume reached 232.9K shares. This is 119.9% of its average volume over the last 100 days. The company's market cap stands at $25.3 million. ASLAN Pharma (NASDAQ:ASLN) shares rose 9.14% to $0.82. The market value of their outstanding shar
Gainers Kaleido Biosciences (NASDAQ:KLDO) stock increased by 24.9% to $0.38 during Thursday's regular session. As of 13:30 EST, Kaleido Biosciences's stock is trading at a volume of 53.0 million, which is 1374.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $16.0 million. Verastem (NASDAQ:VSTM) stock moved upwards by 21.89% to $1.86. As of 13:30 EST, Verastem's stock is trading at a volume of 24.4 million, which is 1316.4% of its average full-day volume over the last 100 days. The company's market cap stands at $347.5 million. Trevi Therapeutics (NASDAQ:TRVI) shares rose 19.06% to $3.31. The current volume of 2.2 million shares
For Immediate Release: September 07, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: As part of the FDA’s effort to protect consumers, the agency issued a warning letter to Kaleido Biosciences, Inc. for not complying with federal laws and regulations, including laws and regulations to protect individuals participatin
BOSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (NASDAQ:RDUS), today announced appointments to new roles on its executive leadership team, effective immediately. Mark Conley has joined Radius as the Company's Chief Financial Officer. In addition, Kim Clarke has been promoted to the General Counsel position. Both will report to Kelly Martin, the Chief Executive Officer. Mark Conley is a Certified Public Accountant with over 30 years of experience in publicly listed companies. His experience includes all aspects of finance including business unit accounting, regulatory, corporate books and records, budget processes, internal & external audit a
CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs. Prior to ORDR, she worked at the U.S. Food and Drug Administration (FDA) Center for
CAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors. Grant brings nearly 40 years of agricultural and corporate leadership, including as Chairman, President, and Chief Executive Officer of the former Monsanto Company, a global provider of technology-based solutions and agricultural products. During h